文献速递甲状腺核医学核素与放射性配体治疗

分化型甲状腺癌术后活动调整131I诊疗的结局

Differentiated Thyroid Cancer Outcomes After Surgery and Activity-Adjusted 131I Theragnostics.
PubMed 文献 · Clin Nucl Med · 2019-01-01

单机构回顾性队列研究纳入350例具有组织病理学危险因素、淋巴结转移和/或远处转移的分化型甲状腺癌患者,术后行诊断性131I扫描(含SPECT/CT)指导活动调整的131I治疗。中位随访39.6±23.4个月,84.3%达完全缓解,2.3%持续碘亲和转移灶需重复131I治疗;31例碘亲和远处转移中42%单次131I治疗即达完全缓解。

要点

  • 术后诊断性131I扫描发现23例(6.6%)未预料残留淋巴结转移并再次颈清扫。
  • 84.3%达完全缓解,12%结构不完全缓解,2.3%持续碘亲和转移需重复131I治疗。
  • 31例碘亲和远处转移中42%单次131I治疗达完全缓解。

核心结论

  • 术后诊断性131I扫描检测区域和远处转移可调整处方131I活动以实现靶向治疗,与固定活动消融相比。
  • 该策略使88%具有组织病理学危险因素和区域转移的患者及42%远处转移患者单次131I治疗后达完全缓解。
  • 大多数结构不完全缓解患者(81%)表现为甲状腺球蛋白升高但随访131I扫描阴性、PET/CT和/或CT阳性,符合肿瘤生物学改变(非碘亲和疾病)。

研究设计与样本

  • 单机构回顾性队列研究,纳入350例分化型甲状腺癌患者,随访1至5年(平均39.6±23.4个月)。
  • 所有患者术后行诊断性131I扫描(含SPECT/CT)以完成分期和风险分层,131I治疗基于组织病理学、刺激后甲状腺球蛋白和闪烁显像信息整合。

主要发现

  • 23例患者(6.6%)因诊断性131I扫描发现未预料残留淋巴结转移而行再次颈清扫。
  • 临床结局:84.3%完全缓解,1.4%生化不完全缓解,2.3%不确定缓解,12%结构不完全缓解。
  • 全队列仅8例患者(2.3%)有持续碘亲和转移性疾病需重复131I治疗。
  • 31例诊断性131I扫描发现碘亲和远处转移的患者中,13例(42%)单次131I治疗达完全缓解。
  • 大多数结构不完全缓解患者(81%)甲状腺球蛋白升高但随访131I扫描阴性、PET/CT和/或CT阳性。

临床怎么用

  • 术后诊断性131I扫描(含SPECT/CT)可用于检测区域和远处转移,并据此调整处方131I活动以实现靶向治疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to determine clinical outcomes in patients with differentiated thyroid cancer after surgery and activity-adjusted I therapy informed by diagnostic I scans with SPECT/CT (Dx scan). METHODS: Single-institution retrospective cohort study analysis of clinical outcomes after 1 to 5 years (mean, 39.6 ± 23.4 months) of follow-up in 350 patients with differentiated thyroid cancer associated with histopathologic risk factors, nodal metastases, and/or distant metastases. Postoperatively, all patients underwent Dx scans for completion of staging and risk stratification, and I therapy was based on integration of information from histopathology, stimulated thyroglobulin and scintigraphy. RESULTS: Twenty-three patients (6.6%) underwent reoperative neck dissection for removal of unsuspected residual nodal metastases identified on Dx scans. Clinical outcomes were as follows: 84.3% complete response, 1.4% biochemical incomplete response, 2.3% indeterminate response, and 12% structural incomplete response. Of the entire cohort, only 8 patients (2.3%) had persistent iodine-avid metastatic disease, which required repeated I therapy. Of 31 patients with iodine-avid distant metastases identified on Dx scans, 13 patients (42%) achieved complete response with a single I treatment. CONCLUSIONS: Detection of regional and distant metastases on postoperative Dx scans permits adjustment of prescribed I activity for targeted treatment, as compared with fixed-activity ablation. This approach resulted in complete response after a single I treatment in 88% patients with histopathologic risk factors and regional metastases and 42% patients with distant metastases. Most patients with structural incomplete response (81%) had elevated thyroglobulin levels with negative follow-up I scans and positive PET/CT and/or CT scans consistent with altered tumor biology (non-iodine-avid disease).

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Avram AM, Rosculet N, Esfandiari NH, et al. Differentiated Thyroid Cancer Outcomes After Surgery and Activity-Adjusted 131I Theragnostics. Clin Nucl Med. 2019. PMID: 30371575. doi:10.1097/RLU.0000000000002321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。